A Short Scale Trial to Study and Evaluate the Safety and Efficacy of a Herbal Composition; Verona Anti-BPH Capsule to Treat Benign Prostatic Hyperplasia in Men Older than 40 Years of Age

Author(s): Ifrah Hasan*, Saba Fatima Naqvi, Amraa Khan, Yamna Hasan, Mir UzairUllah

Journal Name: Current Traditional Medicine

Volume 6 , Issue 4 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Aims and objective: Benign Prostatic Hyperplasia (BPH) is a condition that causes the proliferation of the cells of the prostate causing urine retention, renal insufficiency, bladder calculi, recurrent Lower Urinary Tract Infections (LUTS) and in complicated cases, hematuria with unbearable pain. The trial was conducted to study the safety and efficacy of novel herbal product Verona anti- BPH capsules at a local clinic of Sharafi Goth, Karachi Pakistan.

Introduction: Benign Prostatic Hyperplasia (BPH) is one major condition. The prevalence of the disease increases to around 8-60% in men at the age of 40 years which is caused mainly by hormonal change, lifestyle changes or diet. The disease is mainly defined as increased cellular proliferation of the prostate glands or an enlarged prostate. 50% men of age 65 years and above of the total population of Pakistan are at risk of having Benign Prostatic Hyperplasia (BPH).

Method: This was a single blind, placebo control phase I clinical trial. A total of 35 patients were enrolled in the study, out of which 2 patients got dropped out. 23 patients received Verona anti-BPH capsules and 10 patients received placebo. The sample paired t-test was applied to evaluate the significant level.

Results: Verona Anti-BPH capsules were found safe and effective in the treatment of Benign Prostatic Hyperplasia (anti-BPH).

Conclusion: Verona anti-BPH capsules were known to be effective with no harmful side effects.

Keywords: Herbal composition, Benign prostatic hyperplasia, LUTS, dihydrotestosterone, Seronoa repens, alfuzosin.

[1]
Barrack ER, Berry SJ. DNA synthesis in the canine prostate: effects of androgen and estrogen treatment. Prostate 1987; 10(1): 45-56.
[http://dx.doi.org/10.1002/pros.2990100108] [PMID: 2434936]
[2]
Beckman TJ, Mynderse LA. Evaluation and medical management of benign prostatic hyperplasia Mayo Clinic Proceedings. Elsevier 2005.
[3]
Chapple CR. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 2004; 94(5): 738-44.
[http://dx.doi.org/10.1111/j.1464-410X.2004.05022.x] [PMID: 15329091]
[4]
Coffey DS, Walsh PC. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990; 17(3): 461-75.
[PMID: 1695775]
[5]
DeKlerk DP, Coffey DS, Ewing LL, et al. Comparison of spontaneous and experimentally induced canine prostatic hyperplasia. J Clin Invest 1979; 64(3): 842-9.
[http://dx.doi.org/10.1172/JCI109532] [PMID: 89121]
[6]
Fagelman E, Lowe FC. Herbal medications in the treatment of benign prostatic hyperplasia (BPH). Urol Clin North Am 2002; 29(1): 23-9.
[http://dx.doi.org/10.1016/S0094-0143(02)00015-0] [PMID: 12109350]
[7]
Homma Y, Kawabe K, Tsukamoto T, et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score. Int J Urol 1997; 4(1): 40-6.
[http://dx.doi.org/10.1111/j.1442-2042.1997.tb00138.x] [PMID: 9179665]
[8]
Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol 2017; 4(3): 148-51.
[http://dx.doi.org/10.1016/j.ajur.2017.06.004] [PMID: 29264223]
[9]
Lu-Yao GL, Barry MJ, Chang CH, Wasson JH, Wennberg JE. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Urology 1994; 44(5): 692-8.
[http://dx.doi.org/10.1016/S0090-4295(94)80208-4] [PMID: 7526526]
[10]
McConnell JD. Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urol Clin North Am 1990; 17(3): 661-70.
[PMID: 1695786]
[11]
McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 1990; 17(3): 477-86.
[PMID: 1695776]
[12]
Oesterling JE. Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N Engl J Med 1995; 332(2): 99-109.
[http://dx.doi.org/10.1056/NEJM199501123320207] [PMID: 7527494]
[13]
Roberts N. The selective approach to successful stomal management at home ORL- head and neck nursing Official J Soc Otorhinolaryngol Head-Neck Nurses 13(4): 12-6.
[14]
Rohr HP, Bartsch G. Human benign prostatic hyperplasia: a stromal disease? New perspectives by quantitative morphology. Urology 1980; 16(6): 625-33.
[http://dx.doi.org/10.1016/0090-4295(80)90577-4] [PMID: 6160671]
[15]
Rosenberg MT, Staskin DR, Kaplan SA, MacDiarmid SA, Newman DK, Ohl DA. A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. Int J Clin Pract 2007; 61(9): 1535-46.
[http://dx.doi.org/10.1111/j.1742-1241.2007.01491.x] [PMID: 17627768]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 6
ISSUE: 4
Year: 2020
Published on: 30 July, 2020
Page: [388 - 394]
Pages: 7
DOI: 10.2174/2215083806666200127090140
Price: $25

Article Metrics

PDF: 20
HTML: 4
EPUB: 1
PRC: 1